Nasdaq stocks posting largest percentage increases
AP - Fri Feb 13, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ADHD: 6.92 (+0.73), RCKY: 18.43 (+4.33)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
ALNY: 95.54 (+1.67), BRP: 24.17 (+0.01), ADHD: 6.92 (+0.73), ALSN: 31.88 (+0.24), ACGL: 59.95 (+0.36)
Alcobra's (ADHD) CEO Yaron Daniely on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:45AM CST
ADHD: 6.92 (+0.73)
Alcobra Q4 & FY14 results
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 9:16AM CST
ADHD: 6.92 (+0.73)
Alcobra beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:44AM CST
ADHD: 6.92 (+0.73)
Alcobra Announces Fourth Quarter and Fiscal Year 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Feb 12, 6:36AM CST
-- Conference Call & Webcast at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 6.92 (+0.73)
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 26.06 (+0.18), ALDX: 11.01 (-0.25), ADHD: 6.92 (+0.73), ALXN: 182.29 (+6.02), ALXA: 2.07 (+0.09)
Alcobra Ltd. to Release Fourth Quarter and Fiscal Year 2014 Financial Results and Host Corporate Update Conference Call & Webcast on February 12
GlobeNewswire - Mon Feb 02, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014 before the market open, and will host a corporate update conference call and webcast on Thursday, February 12 at 8:30am Eastern Time.
ADHD: 6.92 (+0.73)
Alcobra Ltd. to Present at BIO CEO & Investor Conference
GlobeNewswire - Thu Jan 29, 7:11AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the upcoming BIO CEO & Investor Conference.
ADHD: 6.92 (+0.73)
Money flow into Alcobra picks up
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 12:50PM CST
ADHD: 6.92 (+0.73)
Can the Uptrend Continue for Alcobra (ADHD)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 6:31AM CST
Can the Uptrend Continue for Alcobra (ADHD)?
ADHD: 6.92 (+0.73)
Alcobra: Options Opportunity In This Rebounding Biotech
Matt Perdue - at Seeking Alpha - Thu Jan 15, 10:03AM CST
ADHD: 6.92 (+0.73)
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Alcobra Ltd. and a Lead Plaintiff Deadline of January 20, 2015
GlobeNewswire - Wed Jan 14, 1:16PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alcobra Ltd. ("Alcobra" or the "Company"
ADHD: 6.92 (+0.73)
Alcobra Ltd. Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Over-Allotment Option
GlobeNewswire - Wed Jan 14, 8:16AM CST
Alcobra Ltd. (Nasdaq:ADHD) today reported that it has closed its previously announced public offering of ordinary shares. The Company sold 7,475,000 ordinary shares in the offering, including 975,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $4.00 per share, and the net proceeds to the Company from the sale of the shares were approximately $27.9 million. Investors in the offering included Venrock, Deerfield, Broadfin Capital, Great Point Partners and others.
ADHD: 6.92 (+0.73)
Rosen Law Firm Reminds Alcobra Ltd. Investors of Important January 19, 2015 Deadline in Class Action - ADHD
GlobeNewswire - Mon Jan 12, 2:05PM CST
Rosen Law Firm reminds purchasers of Alcobra Ltd. common stock (Nasdaq:ADHD) during the period from March 28, 2014 through November 14, 2014, of the important January 19, 2015 deadline in the class action.
ADHD: 6.92 (+0.73)